RBC Capital analyst Gregory Renza reiterates Alnylam Pharmaceuticals (NASDAQ:AGIO) with a Outperform and maintains $55 price target.
- Headlines
- RBC Capital Reiterates Outperform on Alnylam Pharmaceuticals, Maintains $55 Price Target
RBC Capital Reiterates Outperform on Alnylam Pharmaceuticals, Maintains $55 Price Target
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Write a comment
0 0 0
LikeLoveLaughing CryRespectEmmSadAngry
Tap to Select a Mood
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
Use the share button in your browser
to share the page with your friends
Tap here to share
No comments yet. Write one.
Related Stocks Related Stocks
Symbol Mini Chart Latest Price
Unlock the Full List
Latest
13:27
The transaction volume of the Shanghai and Shenzhen stock markets has consecutively exceeded 1 trillion yuan for the 63rd trading day.
13:24
The South Korean president's office stated that they will discuss the legality of the request for impeachment trial.
13:22
The first large medical model for critical care has been released and is already used in the ICU.
TENCENT-0.52%